Executive Summary

By mid-2026, the IL-4 and IL-13 field has moved beyond a one-brand story. One broad dual-pathway franchise now spans multiple specialties, while selective IL-13 antibodies and a China-based IL-4Rα entrant are building narrower but credible positions.

The strategic split is increasingly clear. Receptor-level blockade is winning on indication breadth and platform scale, while selective IL-13 programs are competing through focused dermatology positioning, lifecycle management, and next-wave expansion into younger patients or new diseases.

Market Structure

The marketed set identified in the reviewed materials comprises dupilumab, tralokinumab, lebrikizumab, and stapokibart. Among them, dupilumab and stapokibart target IL-4Rα and therefore block both IL-4 and IL-13 signaling, while tralokinumab and lebrikizumab are selective IL-13 antagonists. That mechanistic split matters commercially because the dual-pathway blockers are the ones with the broadest sourced indication footprints in 2026. 12345678

The class has also entered in sequence rather than all at once. EMA states that Dupixent received EU marketing authorization in 2017, Adtralza in 2021, and Ebglyss in 2023, while the current U.S. labels list initial U.S. approvals of 2021 for ADBRY and 2024 for EBGLYSS. That timing still leaves dupilumab with a substantial maturity advantage relative to the later entrants. 9101135

Approved Products

Dupilumab remains the anchor asset in the IL-4 and IL-13 field. The February 2026 U.S. prescribing information lists nine indications: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis. The current EMA product information supports an equally broad but not identical EU footprint, covering AD, asthma, CRSwNP, PN, EoE, COPD, and CSU. Sanofi also announced additional 2026 approvals for children aged two to 11 years with CSU in the U.S. and for adults with bullous pemphigoid in Japan. 121213

By contrast, tralokinumab and lebrikizumab are still AD specialists in the reviewed Western labels. The current U.S. ADBRY label and EU Adtralza materials support moderate-to-severe AD use in adults and adolescents aged 12 years and older, while the current U.S. and EU Ebglyss labels support moderate-to-severe AD in adults and adolescents aged 12 years and older, with EU labeling specifying body weight of at least 40 kg. In practice, that keeps the selective IL-13 class focused on dermatology rather than the cross-specialty franchise model established by dupilumab. 3456

Stapokibart is the other marketed dual-pathway entrant identified in the source set. China’s NMPA states that it is indicated for adult moderate-to-severe AD, and Keymed’s product materials add China approvals for chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, with all three indications included in the National Reimbursement Drug List as of January 2026. Keymed further reported approximately RMB 310 million in 2025 sales for Kangyueda, indicating that the product has moved beyond a paper launch into early commercial execution in its home market. 7814

View the IL-4 and IL-13 product landscape:

• Open the IL-4 Product Explorer
• Open the IL-13 Product Explorer
• View the IL-4 and IL-13 Target Network

Mechanism and Label Differentiation

The IL-4Rα versus selective IL-13 distinction is central to 2026 positioning. EMA materials state that dupilumab inhibits IL-4 signaling via the type I receptor and both IL-4 and IL-13 signaling through the type II receptor, while the current U.S. label describes it as binding the IL-4Rα subunit and inhibiting IL-4 and IL-13 signaling. Stapokibart likewise targets IL-4Rα and, according to NMPA and Keymed, blocks both IL-4 and IL-13 signaling. That broader pathway coverage aligns with the wider sourced indication reach of the IL-4Rα products. 2178

The selective IL-13 agents are more differentiated from one another than a simple class label implies. EMA materials for tralokinumab state that it neutralizes IL-13 by blocking its interaction with the IL-13Rα1/IL-4Rα receptor complex, while the U.S. Ebglyss label states that lebrikizumab inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex and still allows IL-13 binding to IL-13Rα2. That difference has not yet translated into sourced cross-indication approvals, but it shows why lifecycle strategy in this segment is likely to remain molecule-specific rather than class-generic. 45

Labeling also suggests that ocular monitoring remains a practical issue across the approved set. Dupixent labeling contains a conjunctivitis and keratitis warning, the ADBRY label lists conjunctivitis among common adverse reactions and includes a conjunctivitis and keratitis warning, and the Ebglyss label lists conjunctivitis among its most common adverse reactions. Cross-product safety comparisons should still be made cautiously because the labels summarize different trial programs and indication mixes. 135

Commercial Positioning

Commercial concentration remains extreme. Sanofi reported Dupixent sales of €15.7 billion for full-year 2025 and said Q1 2026 sales again exceeded the €4 billion mark. The breadth of approved uses across dermatology, respiratory disease, and gastroenterology has therefore translated into scale, not just label breadth. 151612

The rest of the landscape is newer and more fragmented. Lilly’s Q4 2025 presentation reported Ebglyss sales of $134 million in the quarter, while LEO’s 2025 annual results discussed Adtralza and Adbry inside a combined strategic brands bucket rather than as a separately disclosed franchise. Keymed reported approximately RMB 310 million in 2025 Kangyueda sales in China. The practical result is a market where scale, disclosure granularity, and geographic reach remain highly uneven outside Dupixent. 171814

That asymmetry matters strategically. For selective IL-13 products, near-term upside appears more likely to come from AD share gains, pediatric expansion, and dosing or persistence narratives than from sudden multi-indication franchise breadth. For IL-4Rα blockers, the nearer-term question is whether any competitor can match dupilumab’s combination of type 2 breadth, regulatory execution, and specialty-spanning reach. The source set does not identify a challenger with comparable breadth today. 121981435

Global IL-4Rα and IL-13 Product Sales Trajectory, 2017-2026

Click to enlarge

Pipeline and Near-Term Catalysts

The most important near-term lifecycle event inside the marketed IL-13 segment is pediatric expansion for lebrikizumab. In March 2026, Lilly reported positive Phase 3 ADorable-1 results in patients aged six months to 18 years with moderate-to-severe AD and said it plans regulatory submissions in the U.S. and other markets for a potential label update. If those filings convert into approvals, Ebglyss could widen its addressable population materially. 19

Beyond marketed products, cendakimab is the most advanced selective IL-13 pipeline asset identified in the reviewed materials outside AD. Bristol Myers Squibb reported that its pivotal Phase 3 eosinophilic esophagitis trial met both co-primary endpoints, with statistically significant reductions versus placebo in dysphagia days and esophageal eosinophil counts and no new safety signals through 48 weeks. A later publication summary on PubMed described statistically significant improvements in symptoms, histologic response, and endoscopic features versus placebo. If approved, cendakimab would extend IL-13 biology deeper into gastrointestinal disease rather than dermatology alone. 2021

Zumilokibart represents the most visible next-wave AD challenge from a pure IL-13 strategy. Apogee reported positive 16-week Part B Phase 2 APEX data in May 2026, said all primary and secondary endpoints were met, and plans to move a mid-dose regimen into Phase 3 in the second half of 2026. Apogee’s pipeline materials also position the molecule for asthma and eosinophilic esophagitis development, suggesting that selective IL-13 competition may increasingly target longer dosing intervals and multi-indication optionality rather than AD alone. 2223

China-based expansion is a separate source of movement. Keymed said in March 2026 that adolescent moderate-to-severe AD filing for stapokibart had been accepted by NMPA, pediatric Phase 3 work was ongoing, and a Phase 3 prurigo nodularis study had completed enrollment in 2025. Those activities do not yet make stapokibart a global franchise, but they do show that the IL-4Rα field is broadening beyond the original Western product base. 14

Outlook

The strategic center of gravity in 2026 is clear. Dupilumab is no longer just the first mover, it is the benchmark for how far IL-4 and IL-13 biology can travel across specialties and patient segments. Everything else in the field is now being judged against one of three standards that Dupixent has already set: breadth of label, pediatric depth, or commercial scale. 121516

For selective IL-13 products, the path forward is narrower but still meaningful. Ebglyss has active pediatric expansion momentum and early commercial uptake, while Adbry and Adtralza remain established AD-only options within LEO’s dermatology business. Pipeline entrants such as cendakimab and zumilokibart show that IL-13 development is not exhausted, but the next phase is more likely to be defined by sharper disease choices, age-segment expansion, and dosing differentiation than by immediate duplication of dupilumab’s franchise breadth. 19171820212223

For IL-4Rα competition, stapokibart shows that regional challengers can build meaningful local franchises and indication-expansion engines, but the reviewed materials do not yet support a conclusion that any entrant is close to matching Dupixent’s cross-market or cross-specialty position. In that sense, the 2026 IL-4 and IL-13 landscape is best understood as one dominant global franchise surrounded by focused specialists and emerging regional or developmental challengers. 8141215